glp-1 drugs review Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping GLP-1 Drugs: 6 Things We've
Description
Meta-analysis of 35 clinical trials demonstrated a modest reduction in LDL cholesterol, total cholesterol, and triglycerides in patients treated with GLP-1 RAs compared to controls (58)
While the risk of kidney injury risk is rare, it is often linked to dehydration from digestive side effects of the drug such as nausea and vomiting
M.et al (2021)
393, no
, 2 GLP-1 , GLP-1
95% CI 0.20-0.51
